---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-302116"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2023-12-22T23:59:59+00:00"
generated_at: "2026-06-07T07:59:12.288988+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics terminates exclusive worldwide license for NOV004 bone fracture repair program

## Summary
- Termination effective October 31, 2023, following prior decision to discontinue internal development of NOV004.
- License was exclusive worldwide under Purdue Research Foundation patents related to bone fracture repair.
- Quince agreed to reimburse PRF for patent prosecution costs and assign development documents to PRF.
- Quince retains internal research rights to assigned documents; PRF must pay Quince 35% if it licenses to certain third parties.

## SEC filing metadata
- accession: 0001193125-23-302116
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2023-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312523302116/0001193125-23-302116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312523302116/d679405d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-302116
- JSON: https://secwatch.observer/filing/0001193125-23-302116.json
- Plain text: https://secwatch.observer/filing/0001193125-23-302116.txt

## Key facts
- Material Agreements
  Quince Therapeutics, Inc. terminated License Agreement with Purdue Research Foundation valued at License terminated; 35% of payments to Company if PRF licenses to certain third parties (effective 2023-10-31).
  - Action: termination
  - Agreement: license
  - Counterparty: Purdue Research Foundation
  - Value: License terminated; 35% of payments to Company if PRF licenses to certain third parties
  - Effective: 2023-10-31
  source text: On December 22, 2023, the Board of Directors of Quince Therapeutics, Inc. (the “Company”), following its prior decision to discontinue internal development of NOV004, approved that certain Mutual Termination of License Agreement (the “Termination Agreement”) by and between the Company and Purdue Research Foundation (“PRF”), to terminate the License Agreement dated June 3, 2020, as amended on March 17, 2022, July 22, 2022, and June 23, 2023 (the “License Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523302116/0001193125-23-302116-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.